Study:
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma
Rationale:
Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving combination
chemotherapy before surgery may make the tumor smaller and reduce the amount of normal
tissue that needs to be removed. Radiation therapy uses high-energy x-rays to kill tumor
cells. Giving radiation therapy after surgery may kill any tumor cells that remain after
surgery. It is not yet known which regimen of myeloablation chemotherapy is more effective
for patients with high-risk neuroblastoma undergoing a peripheral blood stem cell
transplant.
Purpose:
This randomized phase III trial is comparing two different myeloablation therapies
followed by a stem cell transplant in treating young patients with high-risk neuroblastoma.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Neuroblastoma |
Drug: carboplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Drug: thiotepa |
Phase 3 |
Verified by
Children`s Oncology Group
May, 2013
Sponsored by: Children`s Oncology Group
Information provided by: Children`s Oncology Group
ClinicalTrials.gov identifier: NCT00567567
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Julie R. Park, MD., Study Chair